Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (cancer cell proliferation, migration, and invasion[1].
Ficlatuzumab (20 μg/mL; 24 h) effectively decreases tumor-associated fibroblast (TAF)-conditioned media-facilitated HNSCC migration and invasion[1].
Ficlatuzumab (20 μg/mL; 24 h) effectively mitigates TAF-facilitated epithelial-tomesencmal transition (EMT), Vimentin expression in HNSCC cells[1].
Ficlatuzumab (20 μg/mL; 72 h) reduces proliferation induced by TAF-secreted hepatocyte growth factor (HGF) in HNSCC cells[1].
Ficlatuzumab (20 μg/mL; 16 h) reduces the phosphorylation of c-Met and p44/42 MAPK in HNSCC cells compared with cells treated with recombinant HGF alone[1].
[1]. Kumar D, et al. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA Otolaryngol Head Neck Surg. 2015 Dec;141(12):1133-9.